

## Preliminary communication


### Syntheses of L-rubranitrose (2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-L-xylo-hexopyranose) and the naturally occurring D enantiomer

JOHN S. BRIMACOMBE\* and KHANDKER M. M. RAHMAN

Chemistry Department, Dundee University, Dundee DD1 4HN (Great Britain)

(Received January 21st, 1983; accepted for publication, February 3rd, 1983)

Rubranitrose<sup>1</sup> (from rubradirin<sup>2</sup>) is one of three novel, branched-chain nitro sugars that have been found as components of antibiotics in recent years. An X-ray crystallographic study<sup>1</sup> of the  $\beta$ -acetate revealed the relative stereochemistry of rubranitrose to be that of a 2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-xylo-hexopyranose, and, on the basis of its c.d. spectrum, rubranitrose was assigned to the L series. Subsequently, rubranitrose was shown<sup>3</sup> to possess the same absolute configuration as D-kijanose (or D-tetro-nitrose<sup>4</sup>) (1)\*\*, so that its correct structure is 2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-D-xylo-hexopyranose (2).



Before this new evidence came to light, we had embarked on a synthesis of L-rubranitrose (7) based on methyl 3-acetamido-2,3,6-trideoxy-3-C-methyl- $\alpha$ -L-xylo-hexopyranoside<sup>5</sup> (3), a derivative of the novel, branched-chain amino sugar of antibiotic A35512B<sup>6</sup>. Methylation<sup>7</sup> of 3 gave methyl 3-acetamido-2,3,6-trideoxy-3-C-methyl-4-O-methyl- $\alpha$ -L-xylo-hexopyranoside (4, 83%), m.p. 84–85°, [ $\alpha$ ]<sub>D</sub> –125° (c 0.5, chloroform), which we planned to take along the route 4 → 5 → 6 → L-rubranitrose (7). Whereas 4 resisted all attempts to hydrolyse the acetamido group using a variety of strong bases under aqueous conditions, *N*-deacetylation was readily accomplished with calcium in liquid am-

\*To whom enquiries should be addressed.

\*\*The absolute configuration of 1 has been confirmed by a recent synthesis of methyl  $\alpha$ -D-kijanoside<sup>4</sup>.

monia<sup>8</sup> to give methyl 3-amino-2,3,6-trideoxy-3-C-methyl-4-O-methyl- $\alpha$ -L-xylo-hexopyranoside (**5**),  $[\alpha]_D \sim -165^\circ$  (*c* 0.7, chloroform), in 84% yield. Oxidation of **5** with *m*-chloroperoxybenzoic acid in boiling dichloromethane then furnished methyl 2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro- $\alpha$ -L-xylo-hexopyranoside (**6**, 69%), m.p. 92–93°,  $[\alpha]_D -171^\circ$  (*c* 0.7, chloroform), which, on hydrolysis with 0.05M sulphuric acid in aqueous 1,4-dioxane at  $\sim 90^\circ$ , liberated L-rubranitrose (**7**), m.p. 152–154°,  $[\alpha]_D -114.5^\circ$  (7 min)  $\rightarrow -83^\circ$  (*equil.*; *c* 0.4, ethanol); lit.<sup>1</sup> (D enantiomer), m.p. 150–153°,  $[\alpha]_D +127^\circ \rightarrow +86^\circ$  (*equil.*; *c* 1, ethanol). An alternative route to **7** has been outlined recently by Yoshimura and coworkers<sup>9</sup>.

Consequently, our recent synthesis<sup>10</sup> of methyl 3-acetamido-2,3,6-trideoxy-3-C-methyl-4-O-methyl- $\alpha$ -D-xylo-hexopyranoside (the mirror image of **4**) can be regarded as a formal synthesis of D-rubranitrose (**2**), although completion of this work, along the lines indicated above, is presently under way. Ironically, *N*-acetylation of the amino group at the branch-point was discarded in favour of *N*-trifluoroacetylation in another projected route<sup>10</sup> to D-rubranitrose (**2**), because the latter protecting-group is easier to remove. Now that it can be removed efficiently, the more robust *N*-acetyl group is preferred, since it is better suited to some of the earlier transformations involved.

New compounds had elemental analyses and/or spectroscopic properties in agreement with the structures assigned.

#### NOTE ADDED IN PROOF

D-Rubranitrose (**2**), prepared as indicated above, had mp. 154–156°,  $[\alpha]_D +115^\circ$  (7 min)  $\rightarrow +86^\circ$  (*equil.*; *c* 0.5, ethanol).

#### ACKNOWLEDGMENTS

We thank the University of Chittagong for study leave (to K.M.M.R.), and the Commonwealth Scholarship Commission for financial support.

#### REFERENCES

- 1 S. A. Mízsak, H. Hoeksema, and L. M. Pschigoda, *J. Antibiot.*, **32** (1979) 771–772.
- 2 B. K. Bhuyan, S. P. Owen, and A. Dietz, *Antimicrob. Agents Chemother.*, (1965) 91–96; C. E. Meyer, *ibid.*, (1965) 97–99; H. Hoeksema, C. Chidester, S. A. Mízsak, and L. Baczynskyj, *J. Antibiot.*, **31** (1978) 1067–1069; H. Hoeksema, S. A. Mízsak, and L. Baczynskyj, *ibid.*, **32** (1979) 773–776.
- 3 A. K. Mallams, M. S. Puar, and R. R. Rossman, *J. Am. Chem. Soc.*, **103** (1981) 3938–3940.
- 4 K. Funaki, K. Takeda, and E. Yoshii, *Tetrahedron Lett.*, (1982) 3069–3072.
- 5 J. S. Brimacombe, R. Hanna, and L. C. N. Tucker, *Carbohydr. Res.*, **105** (1982) C1–C3.
- 6 M. Debono and R. M. Molloy, *J. Org. Chem.*, **45** (1980) 4685–4687.
- 7 J. S. Brimacombe, B. D. Jones, M. Stacey, and J. J. Willard, *Carbohydr. Res.*, **2** (1966) 167–169.
- 8 G. Stork, S. D. Darling, I. T. Harrison, and P. S. Wharton, *J. Am. Chem. Soc.*, **84** (1962) 2018–2020; A. J. Pearson and D. C. Rees, *J. Chem. Soc., Perkin Trans. 1*, (1982) 2467–2476.
- 9 J. Yoshimura, T. Yasumori, T. Kondo, and K. Sato, *Carbohydr. Res.*, **106** (1982) C1–C3.
- 10 J. S. Brimacombe and K. M. M. Rahman, *Carbohydr. Res.*, **113** (1983) C6–C9.